Skip to main content

Month: September 2020

Private Placement to be Closed on Election Day

Steve Muehler, Founder and Senior Managing Member of the Private Placement Markets, today announced that the Firm will close on Election Tuesday to give all of its Employees, Members, Agents and Participants the Day to Get Out and Vote. Steve Muehler Said, “We have heard the calls to make Election Day a National Holiday, allowing people sufficient time to get to the polls. Without Federal action, Corporate America has been, and needs to continue to step up in a big way to give its employees and even its consumers the day to vote.” Private Placement Markets joins a growing list of U.S. Companies closing its doors on Election Day 2020 to give its people the day to get out in Vote. Companies like Coca-Cola, Best Buy, Gap Inc., J Crew Group, JPMorgan Chase, Lyft, Nike, Twitter and Visa are just a few of the growing number of companies that...

Continue reading

Mobile Banking Market: Recent and Future industry trends by 2026

Technological advancements, surge in consumer acceptance, and significant increase in smartphone usage drive the growth of the global mobile banking market. However, rise in concerns related to security and privacy along with improper connectivity and network infrastructure restrain the market growth. On the other hand, integration of new technologies creates new opportunities in the market. Allied Market Research published a report, titled, “Mobile Banking Market by Transaction (Consumer-to-consumer and Consumer-to-Business), and Platform (Android, iOS, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026.” According to the report, the global mobile banking market garnered $715.3 million in 2018, and is estimated to reach $1.82 billion by 2026, growing at a CAGR of 12.2% from 2019 to 2026. Consumer to...

Continue reading

Elite Capital International: Nasdaq Composite led market together with S&P 500 as Tech shares rises

Technology related shares surge has helped US stocks closed higher on today’s session, as they continue to recover most of its losses from last week. Nasdaq’s back-to-back sessions of advances has led the market higher. Telsa climbed another 7% in today’s session after its 12% jump yesterday… that is roughly 19% rebound in just two days. Even tech giants such as Facebook, Amazon, Netflix and Alphabet also posted gains. Crude oil increased together with Treasuries while dollar has a little change. Here are the main movements in Stock Market this Tuesday; Stocks – Nasdaq Composite ended up with 133.67 points increased or 1.21% to 11,190.32, just before market session closes this Tuesday.– S&P 500 gained about 17.66 points or less than 1% increase to 3,401.20.– The Dow Jones Industrial Average is up with 2.27 points...

Continue reading

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19NEW YORK and LONDON, Sept. 17, 2020 (GLOBE NEWSWIRE) —  Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that it has signed an agreement for a collaborative clinical study investigating nasally administered Foralumab in COVID-19 patients in Brazil, either alone or in combination with orally administered dexamethasone. The Company announced on July 31, 2020 its filing of a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral...

Continue reading

Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing

LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, will ring the Nasdaq stock market closing bell in celebration of the Company’s recent $200 million financing. The virtual ceremony will take place on Monday, September 21, 2020, with formal remarks beginning at 3:45 PM ET.David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, said: “2020 has been a transformative year for Verona Pharma. We have achieved several significant milestones and are preparing to initiate our ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) Phase 3 clinical trials in chronic obstructive pulmonary disease...

Continue reading

G4S plc: Progress on completion of conventional cash transaction

17 September 2020G4S plcProgress on completion of sale of conventional cash businessesG4S, the leading global security company, is pleased to report that, as part of the transaction announced on 26 February 2020, it completed the sale of its conventional cash businesses in Estonia, Latvia and Lithuania on 14 September for aggregate proceeds of around £49 million.G4S has now completed and received approximately 83% of the proceeds anticipated from the sale of its conventional cash businesses to The Brink’s Company.The substantial majority of the remaining completions are scheduled to occur during the remainder of 2020.The sale of the majority of the conventional cash businesses greatly enhances the Group’s strategic, commercial and operational focus and strengthens further its financial position.Notes to Editors:G4S is the leading global...

Continue reading

HEINEKEN Launches New Hard Seltzer Brand

Pure Piraña, developed with all-natural flavours, enters Mexican & New Zealand marketsAmsterdam, 17 September 2020 – HEINEKEN is exploring the Hard Seltzer category with the launch of Pure Piraña in Mexico and New Zealand. It will be available in a choice of up to nine different flavours, enabling HEINEKEN to test local preferences and investigate the potential of a rapidly growing category, whilst also exploring additional market introductions into this category.Pure Piraña demonstrates HEINEKEN’s commitment to crafting new taste profiles in line with consumers’ ever-changing demands. Containing fewer than 100 calories per 330ml can and made with all-natural flavours, the new beverage is aimed at a modern generation of consumers who are increasingly conscious of their consumption habits and lifestyle choices.Jan Derck van Karnebeek,...

Continue reading

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancersNew integrated analyses from our tumour agnostic Rozlytrek® (entrectinib) clinical development programmeBlueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM(pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancerImpact of COVID-19 on cancer care: Roche live virtual panel discussions and Q&As featuring world leading healthcare expertsBasel, 17 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.